EVALUATING THE EFFICACY AND SAFETY OF INAVOLISIB PLUS PALBOCICLIB AND FULVESTRANT VERSUS PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN PATIENTS WITH PIK3CA MUTANT, HORMONE RECEPTOR POSITIVE, HER2 NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER
| Title | EVALUATING THE EFFICACY AND SAFETY OF INAVOLISIB PLUS PALBOCICLIB AND FULVESTRANT VERSUS PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN PATIENTS WITH PIK3CA MUTANT, HORMONE RECEPTOR POSITIVE, HER2 NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER |
|---|---|
| Description | a phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of inavolisib plus palbociclib and fulvestrant versus placebo plus palbociclib and fulvestrant in patients with pik3ca mutant, hormone receptor positive, her2 negative locally advanced or metastatic breast cancer |
| Organism | Homo sapiens |
| Data Type | Biomarker Data |
| Data Accessibility | Controlled-access |
| BioProject | PRJCA021879 |
| Release Date | 2023-12-19 |
| Submitter | Jiong Wu (wujiong1122@vip.sina.com) |
| Organization | Fudan University Shanghai Cancer Center |
| Submission Date | 2023-12-08 |
HTTP download speed may be slow. It is highly recommended that you download the dataset using a dedicated FTP tool (such as FileZilla Client).
| File ID | File Title | Number/Samples | File Type | File Size | File Suffix | Download Times | Download |
|---|---|---|---|---|---|---|---|
| OMIX005354-02 | Clinical data(HER2) | 12 | Biomarker Data | 9.0 KB | xlsx | 0 | Controlled |
| OMIX005354-03 | PIK3CA Gene data | 235 | Biomarker Data | 35.2 KB | zip | 0 | Controlled |